FRM
URGN icon

Fox Run Management’s UroGen Pharma URGN Stock Holding History

Fox Run Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Sell
7,957
-17,714
-69% -$480K 0.05% 681
2026
Q1 		$436K Buy
+25,671
New +$515K 0.08% 501
2025
Q4 		– Sell
-16,902
Closed -$337K – 1286
2025
Q3 		$337K Buy
+16,902
New +$304K 0.05% 641
2025
Q2 		– Sell
-36,271
Closed -$401K – 1256
2025
Q1 		$401K Buy
+36,271
New +$387K 0.06% 577

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fox Run Management's URGN Position: Q2 2026 in Review

Fox Run Management reduced its UroGen Pharma (URGN) stake by 69% in Q2 2026, selling an estimated $480K and leaving 7,957 shares worth $293K. The position accounts for 0.05% of the portfolio, ranked #681.

Fox Run Management first reported a position in URGN in Q1 2025 and has held it in 4 quarters since. The position peaked at $436K in Q1 2026. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Fox Run Management held 7,957 shares of UroGen Pharma worth $293K as of Q2 2026.
  • Fox Run Management sold 17,714 UroGen Pharma shares in Q2 2026, an estimated $480K.
  • UroGen Pharma made up 0.05% of Fox Run Management's portfolio in Q2 2026, its #681 holding.
  • Fox Run Management first reported a position in UroGen Pharma in Q1 2025 and has held it in 4 quarters since.
  • Fox Run Management's UroGen Pharma position peaked at $436K in Q1 2026.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.